Ovarian cancer is the leading cause of ceath from gynecologic malignancies. Despite good response to therapy, a large number of these patients experience relapse. PET/CT is an imaging technology with evolving potential. Its advantage lies in its ability to detect metabolic changes in cancer cells even before the manifestation of the anatomic changes such as (CT). This study aims to evaluate role of PET/CT in early detection of recurrence in the settings of suspected biochemical recurrence with negative or equivocal conventional imaging and in assessment of response to therapy.